HCA:NYSE

HCA’s stock is trading at $545.13, comfortably above its 20‑day ($531.38), 50‑day ($500.89) and 200‑day ($436.90) simple moving averages, reinforcing a bullish technical backdrop. The RSI sits at 61, indicating solid momentum without being overbought, while the MACD histogram is slightly negative, hinting at a short‑term pull‑back risk but the signal line remains near the price. Support around $495 and resistance near $552.9 frame the price action, and volatility of roughly 36% over the last 30 days is elevated yet manageable given the low beta (~0.32) that suggests limited market‑wide swings. Recent earnings beat expectations, with Q4 EPS of $8.01 surpassing forecasts, and revenue grew 6.7% year‑over‑year, underscoring resilient operating performance.
Valuation appears mixed: the trailing P/E of 19.2 is well below the industry average of 25.4, and the forward P/E of 16.4 points to earnings acceleration, supporting a fair‑value case. However, a discounted cash flow model pins fair value near $267, implying the market is pricing in a premium, likely driven by strong cash generation, a modest dividend yield of 0.59% with a low 10% payout, and a $10 billion share‑buyback program. Analyst consensus targets hover around $550, aligning closely with the current price, which suggests limited upside but validates the stock’s defensive positioning in the healthcare sector.